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Abstract
Background: Traditional multiplexed gene expression methods require well preserved, intact
RNA. Such specimens are difficult to acquire in clinical practice where formalin fixation is the
standard procedure for processing tissue. Even when special handling methods are used to obtain
frozen tissue, there may be RNA degradation; for example autopsy samples where degradation
occurs both pre-mortem and during the interval between death and cryopreservation. Although
specimens with partially degraded RNA can be analyzed by qRT-PCR, these analyses can only be
done individually or at low levels of multiplexing and are laborious and expensive to run for large
numbers of RNA targets.
Methods: We evaluated the ability of the cDNA-mediated Annealing, Selection, extension, and
Ligation (DASL) assay to provide highly multiplexed analyses of cryopreserved and formalin fixed,
paraffin embedded (FFPE) tissues obtained at autopsy. Each assay provides data on 1536 targets,
and can be performed on specimens with RNA fragments as small as 60 bp.
Results: The DASL performed accurately and consistently with cryopreserved RNA obtained at
autopsy as well as with RNA extracted from formalin-fixed paraffin embedded tissue that had a
cryopreserved mirror  i m a g e  s p e c i m e n  w i t h  h i g h  q u a l i t y  R N A .  I n  F F P E  t i s s u e  w h e r e  t h e
cryopreserved mirror image specimen was of low quality the assay performed reproducibly on
some but not all specimens.
Conclusion: The DASL assay provides reproducible results from cryopreserved specimens and
many FFPE specimens obtained at autopsy. Gene expression analyses of these specimens may be
especially valuable for the study of non-cancer endpoints, where surgical specimens are rarely
available.
Background
Standard microarray analyses use cDNA synthesized from
the poly-A tail of RNA. It requires highly intact RNA to be
successful. Specimens must be obtained from intact tis-
sues and processed immediately to avoid degradation of
the RNA. Avoiding damage is difficult in clinical settings.
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Autopsy samples may undergo degradation postmortem,
surgical samples may undergo degradation during
processing, and both may be damaged during storage.
Several recent studies demonstrate that real-time PCR can
provide useful gene expression data from clinical speci-
mens, but these assays analyze a single or low number of
expression products. It was shown that gene expression
analysis obtained with reverse transcription PCR from for-
malin-fixed, paraffin-embedded (FFPE) tissues is accurate
and reproducible, and that results were comparable to
those obtained with matching fresh cryopreserved tissue
[1]. Also observed was that neither fixation grade nor
delay in the formalin fixation of the tissue significantly
affected the results. Similar results were also seen by Abra-
hamsen et al [2]. It was observed that a delay in freezing
reduced the amount of total RNA detected, but time in the
fixative seemed to have no effect on relative expression of
mRNA. While informative, the small number of genes
that can be assayed at one time makes assessing gene
expression by qRT-PCR laborious and expensive, limiting
is usefulness in phases of clinical research and medicine
where a broader survey of gene expression is appropriate.
A recently developed cDNA-mediated Annealing, Selec-
tion, extension, and Ligation (DASL) assay (Illumina, San
Diego, California) promises to meet the needs for highly
multiplexed analyses of degraded RNA [3,4]. The DASL
assay is based on highly multiplexed PCR amplification
rather than hybridization. It requires only short (<50 bp)
fragments of RNA, allowing analysis of highly degraded
RNA including cryopreserved and FFPE tissues. In the
assay 1536 RNA probes allow the selection of a specific set
of 512 genes. The assay includes up to three probes per
gene to increase its sensitivity in the analysis of informa-
tive genes. Between 16 and 384 specimens can be assayed
in an experiment using procedures that can be automated
and reagent costs much lower than a standard microarray
[5].
In addition to the archived FFPE samples, frozen autopsy
samples represent a wealth of material as yet underuti-
lized by researchers. Many of these samples sit in freezers
and are considered too degraded for standard microarray
analyses. With the DASL assay we are able to show repli-
cable results attained from degraded specimens such as
these by comparing signal intensities of gene expression
targets.
Methods
Tissue specimens
Anonymous autopsy tissue specimens obtained following
informed consent by next of kin were provided by
Asterand plc. (Detroit, Michigan). Autopsies were per-
formed following a standardized protocol so that speci-
mens were collected in less than eight hours of death.
Each specimen was cut in half to make two mirror image
specimens, one of which was placed immediately in liq-
uid nitrogen and the second was placed immediately in
buffered formalin fixative. The fixed tissue was processed
using an automated processor (Thermo Shandon,
Waltham, Massachusetts) and embedded in paraffin. The
blocks were mounted and sectioned using standard his-
topathologic procedures.
Extraction, quantification, prequalification
RNA from FFPE tissue specimens was extracted from two
5 μm sections from tissue blocks using the High Pure RNA
Paraffin Kit (Roche Diagnostics, Penzberg, Germany)
according to the manufacturer's protocol. This procedure
included an initial deparaffinization with xylene, fol-
lowed by an ethanol rinse and drying. The resulting tissue
pellet was digested with proteinase K and incubated over-
night. The RNA solution was applied to a miniature col-
umn, washed, and eluted into a microcentrifuge tube
using buffers provided by the manufacturer. The eluant
was treated with DNase, followed by a second Proteinase
K digestion, and applied to an additional column. The
RNA on the column was washed again before being
eluted. Typically 28–32 uL of eluant were recovered per
extraction.
Total RNA from cryopreserved tissues was extracted fol-
lowing a protocol developed by Asterand combining the
TRIzol extraction method (Invitrogen, Carlsbad, Califor-
nia) with further cleanup using the RNeasy mini kit pro-
tocol (Qiagen, Valencia, California). The tissue was first
homogenized in Trizol, then 0.2 mL chloroform per mL
Trizol was added, samples were centrifuged and the aque-
ous phase collected. Then 0.5 mL isopropanol per mL TRI-
zol was added and the sample was again centrifuged. After
discarding the supernatant, the pellet was resuspended in
75% ethanol, centrifuged and resuspended in RNase free
water. The RNA was washed on an RNeasy column multi-
ple times and incubated on the column with DNase I for
15 minutes. RNA was quantified from both methods by
the Ribogreen RNA Quantization Assay (Molecular
Probes, Eugene, Oregon).
The RNA quality was analyzed using RNA 6000 Nano
Assay for the Agilent 2100 Bioanalyzer (Agilent Technolo-
gies, Palo Alto, California) by Asterand. All samples were
graded "Passed" or "Failed" based on a grading system
developed by Asterand. The RNA for the cryopreserved
samples was graded from zero to five based on interpreta-
tion of the bioanalyzer profiles. The following criteria
from the Agilent profiles are used for grading RNA quality.
If there is no measurable RNA, the grade is 0. For those
samples with measurable RNA, the following criteria are
each given 1 point for a total score between 1 and 5:BMC Clinical Pathology 2006, 6:9 http://www.biomedcentral.com/1472-6890/6/9
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1. The ratio of 28S to 18S peaks is equal to or greater than
1.3.
2. The area under the 28S and 18S peaks combined is
equal to or greater than 30% of the total area.
3. The widths of the 18S and 28S peaks are each less than
or equal to 4 seconds.
4. There are no distinct peaks between the 28S and 18S
peaks or between the 18S peak and the lower marker peak.
5. The area under the degradation peaks is less than the
combined areas of the 28S and 18S peaks.
Cryopreserved samples with Grades 3 and above based on
this scoring approach were considered "Passing" or quali-
fying for most gene array technologies and those below
Grade 3 as "Failing". This classification is based on
unpublished reports that the likelihood of successful anal-
ysis by conventional microarrays. In addition, each FFPE
specimen was characterized by the grade of its corre-
sponding cryopreserved mirror sample, and divided into
groups according to whether the cryopreserved material
"Passed" or "Failed".
RNA quality in the cryopreserved specimens was also
measured automatically using the RNA integrity number
(RIN) value incorporated into the 2100 Bioanalyzer soft-
ware. This new attribute provides a tool for standardiza-
tion of RNA quality control, in a user-independent,
automated and reliable procedure [6]. The RIN takes into
account decreases of signal intensities for the two ribos-
omal bands and increases in the presence of shorter frag-
ments between the two peaks and below the 18S band.
The FFPE tissues were not graded by the bioanalyzer
except by the quality of the representative cryopreserved
mirror samples, due to the fact that the fixation process
degraded the RNA to an extent that is poorly characterized
by the bioanalyzer profiles.
RNA extractions were pre-qualified for expression analysis
by a real-time PCR assay recommended by Illumina Inc.
[4]. RNA was reverse-transcribed into cDNA using the
Master Mix for cDNA synthesis, single use reagent (Illu-
mina Inc). cDNA was derived from 200 ng of RNA and
was amplified with primers 5'-GTACGCTGTGAAGGCAT-
CAA-3' and 5'-GTTGGTGTTCATCCGCTTG-3' to yield a 90
bp transcript-specific fragment of a highly expressed ribos-
omal protein gene, [GenBank accession # NM_012423.2]
RPL13a. Amplifications were performed with the recom-
mended PCR program, using a commercial SYBR Green
PCR master mix (Applied Biosystems, Foster City, Califor-
nia) and monitored in real-time with a Bio-Rad Icycler
and optical head (Bio-Rad Laboratories, Hercules, Califor-
nia).
DASL gene expression
In the DASL assay (Figure 1) total RNA is converted into
cDNA in a reverse transcription reaction using bioti-
nylated oligo-d(T)18 and random hexamers. Pairs of
query oligos, up to three unique pairs for each of 512
genes, are annealed to complementary sequences (~50
bases) flanking the specified cDNA target site. The bioti-
nylated cDNA is then bound to streptadadivin particles
and mis-hybridized and non-hybridized oligos are
washed away. Through a primer extension and ligation
process the biotinylated ~100 bp DASL product is formed.
This product is then amplified by universal fluorescent
primers using conditions detailed in [4] to fluorescently
label and amplify the templates generated in the pre-PCR
process. The 5' primers (P1 and P2) are labeled with fluo-
rescent Cy3 and Cy5, respectively; while the 3' primer
(P3) contains in addition to its primer sequence an
address sequence which is complementary to a secondary
address sequence located on the Sentrix BeadChip. The
double-stranded PCR products are then isolated and
hybridized to the BeadChips [3,7].
The BeadChip is composed of 16 individual arrays. The
arrays were formed on the slide by densely etching pits
designed to hold silica beads. Each array contains about
50,000 3 μm silica bead derivatized with one of 1,536 dif-
ferent sequences. The beads are positioned randomly, and
a decoding procedure is used to identify the location and
DNA sequence on each bead [8]. After hybridization, the
array is then scanned by laser confocal microscopy using
an automated BeadStation™ Reader and analyzed by Sen-
trixScan™ software from Illumina. The software creates an
intensity data file which is used in statistical analysis of
the results.
Cancer gene panel
The DASL Cancer Panel (Illumina Inc.) includes 1536
unique sequence-specific probes. Genes in the panel were
selected by Illumina based on their importance in previ-
ous studies. Three probes per gene are used for most genes
of interest; allowing for 512 different genes. Probes for
each target within the gene were designed by a proprietary
algorithm developed by Illumina. DASL assays performed
with human genomic DNA as template validated success-
ful analysis of all but 43 of the 1536 probes; the former
were excluded from the expression analysis. All 512 genes
were thus represented with at least 2 probes per gene, with
most represented by three probes.
Statistical analysis
Gene expression data were normalized and differential
expression calculated using algorithms included in Bead-BMC Clinical Pathology 2006, 6:9 http://www.biomedcentral.com/1472-6890/6/9
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Studio Software (Illumina Inc.). Normalization used
robust least squares linear fit with signals of probes which
had small relative rank change (<0.05) between condi-
tions. Number of detectable genes represents the genes for
which the target sequence signal is distinguishable from
the negative controls using a statistical procedure imple-
mented in Beadstudio [9]. Scattergrams representing indi-
vidual relative gene expression were generated using the
Beadstudio program from replicate DASL assays and
squared Pearson correlation coefficients were obtained.
Results and discussion
The RNAs from eleven cryopreserved tissues and 10 for-
malin-fixed, paraffin-embedded tissues were evaluated.
The RNA yields tended to be higher for specimens with a
"Passing" Asterand quality grade (Table 1). This difference
could be attributed to the relative size differences of the
RNA fragments seen in the samples because the RNeasy
columns used in extraction do not retain fragments of
<100 bp. A similar result was seen in the FFPE study,
where tissues that were graded "Failed" RNA in their mir-
rored cryopreserved samples had an average of 81 ng/uL;
whereas those with grades of "Passed" had an average of
120 ng/uL (Table 2). RNA extracts from both sets were
obtained in ~30 uL elution volumes. FFPE samples were
then pre-qualified by RT – PCR using RPL13a primers and
protocol according to Illumina recommendations. The
cycle threshold for intact total RNA controls had an aver-
age of ~26 cycles, while the RNAs from clinical specimens
amplified in 32 or fewer cycles, thus all specimens passed
pre-qualification which requires that the threshold cycles
of the test sample be with seven cycles of control sample.
Bioanalyzer quality measures and scattergrams of the
probe signal intensities for cryopreserved specimens are
illustrated in Figures 2. Intact samples have clear 18S and
28S ribosomal RNA peaks with low amounts of noise
between them and no other peaks in the area before the
18S peak (Fig. 2A). Degradation of RNA leads to 28S
peaks smaller than the 18S peak (Fig. 2B) or even loss of
both peaks as well as increased noise throughout the elec-
tropherograms (not shown). Five samples were graded as
"Passing" according to Asterand methods and six samples
were graded as "Failing" (Table 1). Little difference could
be seen between scattergrams of the replicate analysis of
DASL assays "Passing" RNA and the "Failing" RNA (Figure
2). The squared Pearson correlation coefficients (R2) were
calculated for each sample. The average R2 for samples
with failing RNA was 0.91 and that for samples with pass-
ing RNA was 0.92. These results show that the DASL assay
can be performed reproducibly even on frozen samples
having low quality RNA.
DASL RNA Profiling Technique Figure 1
DASL RNA Profiling Technique (From [5]).BMC Clinical Pathology 2006, 6:9 http://www.biomedcentral.com/1472-6890/6/9
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Figure 3 presents electropherograms of the cryopreserved
RNA sample that is the mirror image of the FFPE samples
analyzed, including a sample with highly intact RNA
(Passing, Rin = 8.9, Figure 3A) and a sample with
degraded RNA (Failing, RIN = 2.3, Figure 3c). Electrophe-
rograms from FFPE tissues, regardless of the RNA quality
of the mirrored cryopreserved sample, have no distin-
guishable peaks, with an average fragment length of about
200 nucleotides (not shown). Even with this severe level
of degradation before fixation as portrayed in Figure 3b
acceptable R2 values can be obtained. Samples with an
Asterand grade of "Failing" have a lower average result (R2
= 0.78 < 0.92) versus that of "Passing" RNA (Table 2), but
still achieved correlation coefficients as high as 0.95.
Overall the R2 values are lower than we have seen in other
analyses (data not shown), a possible reason for this may
be due to the specimens being refrozen multiple times
and samples being run on a number of separate chips.
Table 2: Results for RNA Obtained from Formalin-fixed, Paraffin-embedded Tissue Specimens
Cryopreserved FFPE Tissue
Sample Type Tissue Asterand Quality 
Grade
RIN for Cryoa RIN for FFPEa RNA conc (ng/uL) PCR Ctb # Genes Detectedc Correlation of Replicates (R2) d
1 Kidney Normal Passed 9.2 2.4 153 30 438 0.91
2 Kidney Normal Passed 8.9 2.3 120 25 452 0.98
3 Stomach Normal Passed 8.8 2.4 88 31 310 0.86
Passing RNA Ave 9.0 2.4 120 29 400 0.92
4 Breast Tumor Failed 2.3 1.9 119 30 426 0.95
5 Breast Tumor Failed 2.5 1.2 71 25 338 0.78
6 Lung Tumor Failed 2.4 1.0 54 29 457 0.64
7 Kidney Normal Failed 2.4 2.3 87 32 420 0.91
8 Kidney Normal Failed 2.7 2.3 61 30 229 0.91
9 Kidney Normal Failed NA 2.6 133 32 377 0.69
10 Kidney Normal Failed 2.4 2.4 41 32 164 0.56
Failing RNA Ave 2.5 2.0 81 30 344.4 0.78
NA = Not Available
a RNA Integrity number as assessed by 2100 Bioanalyzer
b Cycle threshold of amplification of RPL-13a, results compared to Ct of intact total RNA
c Genes detected over background by Beadstudio software with a certainty of p = 0.99
d Technical replicates of same RNA extraction run in separate array experiments
Table 1: Results for RNA Obtained from Cryopreserved Tissue Specimens
Sample Type Asterand Quality Grade RINa RNA Conc (ng/μL) # Genes Detectedb Correlation of Replicates (R2)a
1 Brain Passed 7.2 550 425 0.88
2 Brain Passed 8.1 586 411 0.96
3 Brain Passed 8.1 673 425 0.93
4 Brain Passed 7.5 635 391 0.91
5 Brain Passed 6.6 641 391 0.93
Passing RNA Ave 7.5 617 409 0.92
6 Brain Failed 3.1 660 395 0.92
7 Brain Failed 5.8 275 388 0.86
8 Brain Failed 2.5 740 421 0.92
9 Brain Failed 6.2 590 415 0.89
10 Brain Failed 6.5 554 399 0.91
11 Brain Failed 5.8 598 461 0.93
Failing RNA Ave 5.0 569 413 0.91
aRNA Integrity number as assessed by 2100 Bioanalyzer
bGenes detected over background by Beadstudio software with a certainty of p = 0.99
cTechnical replicates of same RNA extraction run in separate array experimentsBMC Clinical Pathology 2006, 6:9 http://www.biomedcentral.com/1472-6890/6/9
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Cryopreserved specimens from autopsies and FFPE RNA
specimens contain a wealth of potential information pre-
viously unavailable for highly multiplexed gene expres-
sion analyses. Currently, researchers using highly
multiplexed gene analyses are limited to working with
only the highest quality cryopreserved tissues. Huang et
al. showed that with standard array procedures the
ischemic time associated with surgical extirpation causes
significant differences in gene expression [10]. A similar
effect was demonstrated in a study involving post mortem
interval and RNA integrity from rat brain tissue. Brain tis-
sue was removed at increasing post mortem time points;
subsequently RNA quality was evaluated by 28S/18S
ribosomal RNA ratio and gene expression was assessed
with cDNA microarray. RNA degradation was seen to
increase and amount of mRNAs detected on the microar-
ray decreased with increasing post mortem interval [11].
In contrast, work with qRT-PCR, which requires only
small fragments for analysis, suggests much less effect of
ischemia or storage. Two studies have looked at RNA deg-
radation in non-fixed human specimens of tonsil, colon,
and breast tissue [12,13]. In both studies respective tissues
were surgically removed and kept at room temperature for
a variety of time points. RNA quality was assessed after
extraction by microchip electrophoresis or gel electro-
phoresis. Gene expression from RNA extracted from these
was assessed using RT-PCR analysis. Both studies show
stable gene expression across the time points.
Results from the DASL assay, which like qRT-PCR requires
only short fragments of RNA, were similar to the qRT-
PCR; reproducible results were able to be obtained with
cryopreserved specimens over a broad range of sample
quality. Bibikova et al has previously shown that repro-
Comparison of Intact and Degraded Cryopreserved RNAs Figure 2
Comparison of Intact and Degraded Cryopreserved RNAs. A. Electropherogram constructed from Bioanalyzer micro-
chip electrophoresis of RNA extracted from cryopreserved tissue graded "Passed" by Asterand quality assessment method. 
Prominent bands can be seen as sharp peaks at 18S and 28S indicating highly intact RNA. C. Sample that did not pass Asterand 
quality measures. Electropherogram shows an 18S peak larger than the 28S peak and an increased amount of noise throughout 
the electropherogram. B. & D. The panels on the right show scattergrams of the signal intensities of individual genes for repli-
cate analyses of each sample, and the associated Pearson correlation coefficient squared (R2). Both samples provided reproduc-
ible results.
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ducibility of the DASL in gene expression profiling com-
pared to that of qRT-PCR. Good correlations were shown
between qRT-PCR Cts and DASL signal intensity in fresh-
frozen samples (R2 = 0.88) [3]. A lower correlation was
observed between qRT-PCR and DASL results for FFPE tis-
sue, which the author attributed to less sensitivity and
reproducibility of the qRT-PCR assay.
We further examined whether reproducibility of assay
results was influenced by the level of expression of indi-
vidual genes. Based on signal intensity, the correlation
coefficients for replicate arrays was examined for the 100
most highly expressed genes, and compared to the corre-
lation coefficients for the lowest expressed 100 genes for
each fixation method. For cryopreserved tissue, the aver-
age squared Pearson correlation coefficients were high in
both groups, regardless of whether the sample had a pass-
ing or failing grade (range 0.64 – 0.82). For the FFPE tissue
the correlation coefficients for replicate analyses were
acceptable for the 100 most highly expressed genes, but
poor for the 100 least highly expressed genes.
The result of this study suggests approaches to validating
results obtained from FFPE tissues. Firstly, the reproduci-
Comparison of Intact and Degraded FFPE Extracted RNAs Figure 3
Comparison of Intact and Degraded FFPE Extracted RNAs. A. Electropherogram of RNA graded "Passed" by 
Asterand quality measures from cryopreserved tissue of a mirror image preparation of the FFPE sample being studied. One can 
see clear peaks for both 18S and 28S ribosomal RNA with low amount of noise between the peaks. C. Cryopreserved mirror 
sample graded "Failed" by Asterand quality measure. A lack of distinguishable peaks and also a large amount of fragments in the 
low molecular weight range indicates a large amount of degradation. B. & D. The right shows the reproducibility of the assay 
based on scattergrams of signal intensities from extracted FFPE RNA on replicate DASL assays and the obtained Pearson R2 
correlation coefficient squared (R2). Both scattergrams demonstrate highly reproducible results.
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bility of the assays could be assessed by comparing results
for replicate arrays. Secondly, when assaying FFPE tissue,
the replicablity of the array could be increased by exclud-
ing lower expressed from the analysis. This would reduce
the data obtained from the array, but could be used if run-
ning duplicate arrays was not an option. A less expensive
pre-qualification measure, and more practical approach
to the assaying of these specimens is needed, but the
development of such an approach is outside the scope of
this study.
Conclusion
The DASL assay is an innovative microarray based on qRT-
PCR technology that allows researchers to conduct high-
throughput, highly-multiplexed gene expression array
analyses of tissues that otherwise could only be analyzed
by qRT-PCR. It provides reproducible results from cryop-
reserved specimens and many FFPE specimens obtained at
autopsy. Gene expression analyses of these specimens
may be especially valuable for the study of non-cancer
endpoints, where surgical specimens are rarely available.
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